These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 19324166)
1. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels. Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Bánfalvi T; Gilde K; Boldizsár M; Kremmer T Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105 [TBL] [Abstract][Full Text] [Related]
4. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1). Ye Z; Kageshita T; Ishihara T; Ito S; Ono T J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560 [TBL] [Abstract][Full Text] [Related]
5. Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy. Kikuchi K; Wakamatsu K; Tada Y; Komine M; Ito S; Tamaki K Clin Exp Dermatol; 2008 Nov; 33(6):750-3. PubMed ID: 18954414 [TBL] [Abstract][Full Text] [Related]
6. Increased serum levels of 5-S-cysteinyldopa and intercellular adhesion molecule-1 in a patient with a uterine amelanotic metastasis from a primary vaginal malignant melanoma. Suenaga Y; Katabuchi H; Okamura H; Kageshita T; Ono T Gynecol Oncol; 1999 Jan; 72(1):107-10. PubMed ID: 9889040 [TBL] [Abstract][Full Text] [Related]
7. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180 [TBL] [Abstract][Full Text] [Related]
8. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605 [TBL] [Abstract][Full Text] [Related]
9. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma]. Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024 [TBL] [Abstract][Full Text] [Related]
10. High serum level of 5-S-cysteinyldopa in chronic renal failure does not always indicate melanoma progression. Asada Y; Arakawa S; Fujiwara S; Sato F; Kaneda K Br J Dermatol; 2004 Aug; 151(2):515-6. PubMed ID: 15327571 [No Abstract] [Full Text] [Related]
11. Improved method for analysis of cysteinyldopa in human serum. Arstrand K; Kullman A; Andersson R; Rasmuson T; Kågedal B Scand J Clin Lab Invest; 2004; 64(6):559-64. PubMed ID: 15370461 [TBL] [Abstract][Full Text] [Related]
12. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid. Agrup G; Andersson T; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E Acta Derm Venereol; 1975; 55(1):5-6. PubMed ID: 46673 [TBL] [Abstract][Full Text] [Related]
13. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021 [TBL] [Abstract][Full Text] [Related]
14. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients. Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152 [TBL] [Abstract][Full Text] [Related]
15. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients. Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361 [TBL] [Abstract][Full Text] [Related]
16. [Significance of 5-S-cysteinyldopa on primary malignant melanoma of the female genital organs]. Takehara M; Mizuuchi H; Ito E; Hayakawa O; Takashima S; Nei H; Kudo R; Horikoshi T; Ito S Nihon Sanka Fujinka Gakkai Zasshi; 1992 Mar; 44(3):369-72. PubMed ID: 1607763 [No Abstract] [Full Text] [Related]
17. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Hasegawa M; Takata M; Hatta N; Wakamatsu K; Ito S; Takehara K Melanoma Res; 1997 Jun; 7(3):243-51. PubMed ID: 9195564 [TBL] [Abstract][Full Text] [Related]
19. Primary malignant melanoma of the lung: review of literature and report of a case. Reddy VS; Mykytenko J; Giltman LI; Mansour KA Am Surg; 2007 Mar; 73(3):287-9. PubMed ID: 17375790 [TBL] [Abstract][Full Text] [Related]
20. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography. Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]